The overarching goals of this study are to measure levels of circulating tumor DNA (ctDNA) in patients with early stage diffuse large B cell lymphoma (DLBCL), to assess the change in ctDNA during treatment in order to prospectively identify markers of treatment failure, and to use ctDNA as a future tool for response adapted therapy.
Previously untreated limited stage non bulky DLBCL; defined as limited stage by routine staging criteria in lymphoma involving FDG-PET and bone marrow biopsies (the Lugano criteria)[21]
Patients with grade 3B follicular lymphoma and transformed indolent lymphoma are included
Ages ≥ 18
Measurable disease, assessable by radiographic examination with FDG-PET showing involvement
Pregnancy, positive serum HCG within 28 days of enrollment, or breast-feeding
Bulky disease greater than 10 cm in any dimension